Lisata Therapeutics and GATC Health see collaboration as the way forward for drug development

Proactive - Interviews for investors

Lisata Therapeutics Inc CEO Dr David Mazzo and GATC Health chief business officer Tyrone Lam talked with Proactive's Stephen Gunnion about the companies' collaboration to advance a novel treatment for opioid use disorder. Mazzo explained that combining Lisata’s regulatory and clinical expertise with GATC’s MAT artificial intelligence platform allows the team to significantly reduce the trial-and-error typical in early drug development. “The reason that we've expanded the partnership is that we see a real symbiotic relationship between the two organizations,” Mazzo said. He highlighted that the AI platform has enabled the identification of promising candidates much faster than conventional approaches. This first program targets opioid abuse, which Mazzo described as a large unmet medical need and a significant social issue in the United States. He noted the market potential could be valued in the billions of dollars, creating both commercial and social opportunities. Mazzo also discussed how the partnership model could lead to either independent commercialization or licensing deals with larger pharmaceutical companies. Throughout the discussion, both Mazzo and Lam emphasized that the combination of AI and biotech expertise may serve as a model for future drug development collaborations. Visit Proactive’s YouTube channel for more videos. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content. #LisataTherapeutics #GATCHealth #OpioidCrisis #DrugDiscovery #ArtificialIntelligence #BiotechInnovation #MATPlatform #OpioidUseDisorder #ClinicalTrials #NonOpioidTreatment